Researchers may have found a new way to weaken glioblastoma’s defenses against treatment. Blocking a protein called SET prevented tumors from forming in preclinical models, while targeting related proteins made cancer cells more vulnerable to radiation. The strategy works by restoring the activity of PP2A, an enzyme that glioblastoma cells appear to suppress. Human trials will be needed to determine whether the approach is safe and effective.